通过激活Nrf2-ARE通路,设计和合成具有抗作用的新型环糖胺
Walaa H Abd-Allah1, Mohammed S Abdel-Maksoud2, Marawan A Elbaset3
1Pharmaceutical Chemistry Department, Collage of Pharmaceutical Science and Drug Manufacturing, Misr University for Science and Technology, P.O. 77, 6th of October City, Giza, Egypt.
Bioorganic chemistry
|March 15, 2025
概括
新型环糖胺衍生物显示出显著的抗和神经保护作用. 这些化合物,特别是6d,通过Nrf2/ARE通路提供强大的抗发作保护和神经保护,没有观察到神经毒性.
科学领域:
- 药用化学 医学化学
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 和神经退行性疾病带来了重大挑战.
- 新型抗和神经保护剂的开发至关重要.
- 环素碳胺衍生物代表了一类有前途的化合物.
研究的目的:
- 合成和评估新型循环糖胺衍生物的抗和神经保护作用.
- 研究作用机制,包括通过Nrf2/ARE通路进行神经保护.
- 评估这些化合物作为神经系统疾病治疗药物的潜力.
主要方法:
- 循环糖胺衍生物 (4a-e,5a-e,6a-e) 的合成.
- 使用最大电击 (MES) 和皮下乙 (scPTZ) 发作模型进行抗药评价.
- 通过氧化应激标记,Nrf2/ARE通路激活,组织病理学和分子对接来评估神经保护.
主要成果:
- 化合物5a和6b在MES测试中显示出100%的保护;4b,5c和6d在scPTZ测试中显示出83.33%的保护.
- 化合物6d在scPTZ测试中表现出优越的活性 (ED50 = 0.04 mmol/kg),表现优于巴比他和埃索苏西米德.
- 神经保护作用与氧化应激调节和Nrf2/ARE通路激活有关,由组织病理学和分子对接证实.
结论:
- 合成的环糖胺衍生物具有显著的抗和神经保护性质.
- 化合物6d是一个非常有前途的候选物,显示出强大的疗效和有利的安全性.
- 这些发现支持进一步开发这些衍生品作为潜在的抗和神经保护剂.
相关概念视频
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
207
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
207
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
303
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
303
01:14Antiepileptic Drugs: Glutamate Antagonists
266
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
266
01:28Structure-Activity Relationships and Drug Design
474
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
474